|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120,400.00 KRW | +3.61% |
|
0.00% | -3.37% |
| 01-12 | SK Biopharmaceuticals Secures FDA Approval for New Drug Testing | MT |
| 12-29 | IT Chem Wins Drug Consignment Production Deal from SK Biotek | MT |
| Capitalization | 9,429B 6.44B 5.47B 5.07B 4.74B 8.84B 591B 9.37B 57.99B 23.02B 279B 24.14B 23.64B 1,016B | P/E ratio 2025 * |
53.9x | P/E ratio 2026 * | 35.5x |
|---|---|---|---|---|---|
| Enterprise value | 9.13B 6.24M 5.3M 4.92M 4.59M 8.56M 573M 9.08M 56.18M 22.31M 271M 23.38M 22.91M 984M | EV / Sales 2025 * |
12.8x | EV / Sales 2026 * | 9.94x |
| Free-Float |
35.81% | Yield 2025 * |
-
| Yield 2026 * | 0.08% |
| 1 day | +3.61% | ||
| Current month | -3.37% | ||
| 1 month | -6.30% | ||
| 3 months | +13.26% | ||
| 6 months | +18.39% | ||
| Current year | -3.37% |
| 1 week | 112,100 |  | 120,700 |
| 1 month | 112,100 | | 127,900 |
| Current year | 112,100 | | 127,900 |
| 1 year | 86,900 | | 144,100 |
| 3 years | 57,600 | | 144,100 |
| 5 years | 50,900 | | 155,000 |
| 10 years | 50,900 | | 269,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong-Hoon Lee
CEO | Chief Executive Officer | 58 | 31/12/2022 |
Ji-Young Jeong
DFI | Director of Finance/CFO | 53 | - |
Chang-Ho Yu
PRN | Corporate Officer/Principal | 51 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Min-Ji Kim
BRD | Director/Board Member | 54 | 27/03/2023 |
Hae-Young Ahn
BRD | Director/Board Member | 69 | 26/08/2019 |
Min-Seop Song
BRD | Director/Board Member | 56 | 26/08/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +8.61% | 0.08% | 20 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.61% | 0.00% | +10.76% | +67.92% | 6.44B | |
| -0.55% | -1.77% | -11.57% | -33.73% | 65.28B | |
| +1.59% | +3.16% | +15.53% | -7.93% | 8.78B | |
| -2.90% | -2.79% | +24.43% | +34.62% | 8.14B | |
| +3.24% | +0.28% | -15.40% | +112.75% | 5.51B | |
| -1.70% | +1.32% | +176.36% | +34.57% | 4.12B | |
| +3.10% | -1.25% | -11.47% | -19.93% | 2.97B | |
| -1.73% | -3.50% | +24.87% | +17.17% | 2.77B | |
| -4.86% | -4.76% | +48.65% | +36.38% | 2.64B | |
| Average | -0.02% | -0.54% | +29.13% | +26.87% | 11.85B | |
| Weighted average by Cap. | -0.19% | -0.88% | +4.25% | -6.60% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 711B 485M 413M 383M 358M 667M 44.59B 706M 4.37B 1.74B 21.05B 1.82B 1.78B 76.58B | 901B 615M 523M 485M 453M 844M 56.48B 895M 5.54B 2.2B 26.67B 2.31B 2.26B 97.01B |
| Net income | 175B 119M 101M 93.92M 87.76M 164M 10.95B 173M 1.07B 426M 5.17B 447M 438M 18.8B | 266B 181M 154M 143M 134M 249M 16.66B 264M 1.63B 649M 7.87B 680M 666M 28.62B |
| Net Debt | -294B -201M -171M -158M -148M -276M -18.44B -292M -1.81B -718M -8.7B -752M -737M -31.66B | -477B -326M -277M -257M -240M -447M -29.94B -474M -2.94B -1.17B -14.13B -1.22B -1.2B -51.42B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 120,400.00 ₩ | +3.61% | 244,239 |
| 22/01/26 | 116,200.00 ₩ | +1.93% | 228,238 |
| 21/01/26 | 114,000.00 ₩ | -4.36% | 330,580 |
| 20/01/26 | 119,200.00 ₩ | +0.85% | 191,695 |
| 19/01/26 | 118,200.00 ₩ | -1.83% | 277,252 |
End-of-day quote Korea S.E., January 22, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A326030 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition